Division of Neurology, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil.
Epilepsy Res. 2010 Feb;88(2-3):108-11. doi: 10.1016/j.eplepsyres.2009.10.003. Epub 2009 Nov 5.
To report the frequencies of Val66Met polymorphism in patients with temporal lobe epilepsy (TLE) compared to normal controls. We also investigated whether Val66Met promoted differences in major clinical variables of TLE.
A case-control study comparing the frequencies of Val66Met polymorphism in 101 Caucasian TLE patients and in 104 Caucasian normal matching controls. In the second step, we evaluated the patient group in terms of the major clinical and electrographic variables related to the epileptogenic process.
The frequency of Val66Met polymorphism did not differ between epileptic patients and normal controls. Moreover, the Val66Met polymorphisms did not influence age of epilepsy onset, duration of epilepsy, control of seizures, or extension of the irritative zone. Also, the groups did not differ in terms of family history of epilepsy and presence of aura.
In spite of abundant evidence that Val66Met BDNF polymorphism has an impact on several different neurological or psychiatric disorders, we conclude that a major clinical impact of Val66Met polymorphism as a disease modifier in temporal lobe epilepsy is probably unlikely.
报告颞叶癫痫（TLE）患者与正常对照相比，Val66Met 多态性的频率。我们还研究了 Val66Met 是否促进了 TLE 的主要临床变量的差异。
一项病例对照研究比较了 101 例白种人 TLE 患者和 104 例白种人正常匹配对照的 Val66Met 多态性频率。在第二步中，我们根据与致痫过程相关的主要临床和电描记变量评估患者组。
癫痫患者和正常对照组之间 Val66Met 多态性的频率没有差异。此外，Val66Met 多态性并不影响癫痫发作的年龄、癫痫发作的持续时间、癫痫发作的控制或刺激性区域的扩展。此外，两组在癫痫家族史和出现先兆方面也没有差异。
尽管有大量证据表明 Val66MetBDNF 多态性对多种不同的神经或精神疾病有影响，但我们得出结论，Val66Met 多态性作为颞叶癫痫疾病修饰因子的主要临床影响可能不太可能。
